Drug Profile
OVX 836
Alternative Names: OVX-836Latest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator OSIVAX
- Class Influenza virus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 15 Jan 2024 Osivax completes a phase IIa trial for Influenza virus infections (Prevention) in Australia (IM, Injection) (NCT05734040)
- 05 Dec 2023 Osivax plans preclinical study against two pandemic influenza A-strains pH1N1 and H5N1
- 11 Oct 2023 Immunogenicity and adverse events data from a phase IIa clinical trial in healthy volunteers released by Osivax